ClinicalTrials.gg
CompletedNCT05299931REScUE-OLEUpdated Oct 13, 2026

An Open-Label Extension and Long-term Efficacy and Safety Monitoring Study of Patients With Crohn's Disease Previously Included in the Loss of RESponse to Ustekinumab Treated by Dose Escalation Study

A Phase 3 interventional study of Ustekinumab in Crohn Disease, sponsored by Belgian Inflammatory Bowel Disease Research and Development (BIRD) VZW. Completed at 1 site in Belgium. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-13.

Sponsored by Belgian Inflammatory Bowel Disease Research and Development (BIRD) VZW · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 4 months after the study started (first participant enrolled Sep 2021, registered Feb 2022).
Updated Oct 13, 2026Now CompletedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
41
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 21 studies testing ustekinumab in Crohn Disease — 3 open to participants now, 5 under way, 2 of them phase 3. Ustekinumab · Crohn Disease.

Enrollment
17th of 21
41 · median 131
Started
2021
with 3 others
Phase 3
8 of 21
none open now
Registered
18th of 21
by date
Lead sponsor
2 of 21
Belgian Inflammatory Bowel Disease Research and Development (BIRD) VZW

Among the 21 studies testing ustekinumab in Crohn Disease, this one is the 17th largest by enrollment, is one of 4 that started in 2021, is one of 8 in phase 3, and was the 18th registered.

Crohn Disease

1,995 studies on the registry are indexed under Crohn Disease; 477 are open to participants now.

Browse Crohn Disease studies →

Open to participants now

3 of the 21 studies testing ustekinumab in Crohn Disease are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About ustekinumab

Ustekinumab: first FDA approval 2009 (STELARA), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 353 Crohn Disease studies recruiting now, 155 (44%) set no upper age limit and 143 (41%) stop at 75 or younger; 94 take children under 18; 56 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies testing ustekinumab in Crohn Disease, or all of them as a file.
02

Study summary

The aim of the study is to assess the long-term efficacy and safety of a ustekinumab 90mg subcutaneous (SC) every 4 weeks (Q4w) regimen in patients with Crohn's disease previously enrolled in the REScUE study (NCT04245215) because of secondary loss of response to a ustekinumab 90mg SC every 8 weeks (Q8w) regimen.

Read the detailed description

The study is a prospective, open-label study only enrolling patients that were previously included in the REScUE study (n=max. 108; NCT04245215) and that terminated that study at week 48. Patients will undergo most necessary examinations, including endoscopy, as part of the Week 48 visit of the REScUE study and those should therefore not be repeated as part of Week 0 visit of the REScUE-OLE study (W0 REScUE-OLE = W48 REScUE). The FACIT-Fatigue scale and the additional laboratory evaluations (serum creatinine, ALT, AST and conjugated bilirubin) are the only examinations that are not foreseen at the end of the REScUE study at week 48. During the 4-week period following the start of REScUE-OLE (= end of REScuE at Week 48), collection and monitoring of the patient's data within the REScUE study will first be finalized, after which unblinding takes place. Depending on the final outcome and treatment of the patient in REScUE ("Q8w responders", "Q8w non-responders", "Q4w responders"), the OLE treatment regimen will be decided as follows:

  1. Patients previously enrolled to the ustekinumab 90 mg SC Q8w-arm will continue ustekinumab 90 mg SC Q8w if they are "Q8w responders" at the end of REScUE, defined by the following criteria:

    • Concomitant steroid use \<= 20 mg prednisone equivalents (budesonide \<=6 mg; beclomethasone dipropionaat \<= 5 mg) for at least 28 days before the end of REScUE at week 48 AND
    • Clinical remission (defined as average AP \<=1 and average SF \<=3) OR clinical response (defined as a drop of at least 50% in average AP and/or a drop of at least 50% in average SF as compared to REScUE baseline, and both average AP and SF no worse than REScUE baseline) AND
    • Endoscopic remission (defined as a total SES-CD \<5) OR endoscopic response (defined as a drop of at least 50% in total SES-CD score as compared to REScUE baseline)
  2. Patients previously enrolled to the ustekinumab 90 mg SC Q8w-arm will switch to ustekinumab 90 mg SC Q4w ("Cross-over") if they are "Q8w non-responders" at the end of REScUE, defined as failing to meet the criteria for continuation of ustekinumab 90 mg SC Q8w as described above (in 1).
  3. Patients previously enrolled to the ustekinumab 90 mg SC Q4w-arm will continue ustekinumab 90 mg SC Q4w if they are "Q4w responders" at the end of REScUE, defined by the following criteria:

    • Concomitant steroid use \<=20 mg prednisone equivalents (budesonide \<=6 mg; beclomethasone dipropionaat \<=5 mg) for at least 28 days before the end of REScUE at week 48 AND
    • Clinical remission (defined as average AP \<=1 and average SF \<=3) OR clinical response (defined as a drop of at least 50% in average AP and/or a drop of at least 50% in average SF as compared to REScUE baseline, and both average AP and SF no worse than REScUE baseline) AND
    • Endoscopic remission (defined as a total SES-CD \<5) OR endoscopic response (defined as a drop of at least 50% in total SES-CD score as compared to REScUE baseline)
  4. Patients previously enrolled to the ustekinumab 90 mg SC Q4w-arm will be excluded from continuation of treatment within REScUE-OLE ("Screen failure") if they are "Q4w non-responders" at the end of REScUE, defined as failing to meet the criteria for continuation of ustekinumab 90 mg SC Q4w as described above (in 3).

The consecutive CD treatment after REScUE-OLE cessation is at the discretion of the treating physician.

During the REScUE-OLE study, patients will have on-site, scheduled visits at 5 different timepoints. At each of these visits, the following study procedures will take place: registration of current (CD and non-CD) treatment, assessments of (serious) adverse events, disease activity assessment (PRO-2), physical examination, weight assessment, assessment of vital signs (blood pressure and pulse), laboratory evaluation (including CRP, haemoglobin, thrombocytes, serum albumin, serum creatinine, ALT, AST, conjugated bilirubin, and FC), patient diary review and instruction, and administration of commercially available ustekinumab 90 mg SC. At week 56 and at the end of the study at week 112, these study procedures will be complemented with pharmacokinetic sampling, an ileocolonoscopy and a monitoring of quality-of-life, work and productivity impairment and fatigue, using dedicated questionnaires. For all visits, a window of maximum 7 days is authorized. In between on-site visits, the administration of the medication is allowed off-site, following the schedule of the OLE treatment arm in which they are allocated. This can either be done by self-administration, for patients who have been trained to self-administer, or by a qualified medical professional.

Steroid use at the start and during the study is possible, but a strict tapering regimen is mandatory. Dose-escalation or (re-)initiation of steroids is allowed for a maximum of two times during the study period, with at least 6 months between the first and the second steroid dose-escalation/(re-)initiation. Patients treated with ustekinumab 90 mg SC Q8w will be able to cross-over to a ustekinumab 90 mg SC Q4w regimen if they meet the criteria of CD worsening at week 12 or at any timepoint beyond week 12 after entering REScUE-OLE. Patients treated with a OLE treatment regimen of ustekinumab 90 mg SC Q4w will stop the REScUE-OLE study and discontinue ustekinumab within the REScUE-OLE study, if they meet the criteria of CD worsening at two different timepoints (separated by at least 4 weeks) beyond week 12 after initiation of this OLE treatment regimen.

Primary endpoint of the REScUE-OLE study (sustained steroid-free clinical remission) will be assessed at week 112.

03

Conditions studied

  • Crohn Disease

Browse trials for

Keywords

  • ustekinumab
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Previous inclusion in the REScUE study and having reached the end of this study at week 48.
  2. Adequate in females of reproductive age (oral, transdermal, injectable contraception, intra-uterine device, sterilisation or barrier method). Adequate contraception in males (sterilization or barrier method) if his female partner is of reproductive age.
  3. Have the capacity to understand and sign an form.
  4. Be able to adhere to the study visit schedule and other protocol requirements.

Exclusion criteria

Exclusion Criteria:

  1. Patients previously enrolled to the ustekinumab 90 mg SC Q4w-arm during REScUE who were on concomitant use >20 mg prednisone equivalents (budesonide >6 mg; beclomethasone dipropionaat >5 mg) at any time point in the last 28 days before the end of REScUE at week 48.
  2. Patients previously enrolled to the ustekinumab 90 mg SC Q4w-arm during REScUE that did not reach the following criteria at the end of REScUE at week 48:

    • Clinical remission (defined as average AP\<=1 and average SF\<=3) OR clinical response (defined as a drop of at least 50% in average AP and/or a drop of at least 50% in average SF as compared to REScUE baseline, and both average AP and SF no worse than REScUE baseline) AND
    • Endoscopic remission (defined as a total SES-CD \<5) OR endoscopic response (defined as a drop of at least 50% in total SES-CD score as compared to REScUE baseline)
  3. Patients who developed an anaphylactic or severe allergic reaction to study medication during REScUE.
  4. Patients with any of the following laboratory tests at W0 of the REScUE-OLE study :

    • level \<8.5 g/dL
    • level \<100.000 /mm3
    • Serum creatinine level ≥1.7 mg/dL
    • and ALT level >3 times the
    • Direct (conjugated) level ≥3.0 mg/dL
  5. Patients with an ongoing treatment with another concomitant biological (vedolizumab, anti-TNF), a JAK-inhibitor or any product for the treatment of Crohn's disease at the end of REScUE at week 48.
  6. Patients who experience or have an ongoing infection event confirmed by positive stool or blood testing (including gastrointestinal pathogens, tuberculosis, , , ) should not initiate REScUE-OLE until (i) this event has completely resolved as shown by the termination of treatment with anti-infective medication, or (ii) this event is considered to be in stable remission under anti-infective medication in case of HIV, hepatitis B and hepatitis C.
  7. Patients with an impassable stenosis even after attempt of endoscopic balloon dilatation.
  8. Patients with an intra-abdominal abscess, or patients with an intra-anal abscess without adequate drainage by e.g. a seton placement.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
41 participants (actual)

Study arms

  • Other
    Subcutaneous (SC) ustekinumab every 8 weeks (Q8w)

    Patients previously enrolled to the ustekinumab 90 mg SC Q8w-arm will continue ustekinumab 90 mg SC Q8w if they are "Q8w responders" at the end of REScUE Patients treated with a OLE treatment regimen of ustekinumab 90 mg SC Q8w will be able to cross-over to a OLE treatment regimen of ustekinumab 90 mg SC Q4w if they meet the criteria of CD worsening at week 12 or at any timepoint beyond week 12 after entering REScUE-OLE

    Drug: Ustekinumab

  • Other
    Subcutaneous (SC) ustekinumab every 4 weeks (Q4w)

    Patients previously enrolled to the ustekinumab 90 mg SC Q8w-arm will switch to ustekinumab 90 mg SC Q4w ("Cross-over") if they are "Q8w non-responders" at the end of REScUE OR Patients previously enrolled to the ustekinumab 90 mg SC Q4w-arm will continue ustekinumab 90 mg SC Q4w if they are "Q4w responders" at the end of REScUE

    Drug: Ustekinumab

Interventions

  • dose escalation from every 8 weeks to every 4 weeks only in arm 2

    Also known as: dose escalation only in arm 2

06

What researchers measure

Primary outcomes

  1. Proportion of patients in both treatment arms in steroid-free clinical remission

    Proportion of patients in both treatment arms in steroid-free clinical remission (PRO-2 remission: average AP \<=1 and average SF \<=3 without any steroid use in the previous 28 days) at both week 56 and week 112 of the study (sustained steroid-free clinical remission).

    Time frame: Week 56

  2. Proportion of patients in both treatment arms in steroid-free clinical remission

    Proportion of patients in both treatment arms in steroid-free clinical remission (PRO-2 remission: average AP \<=1 and average SF \<=3 without any steroid use in the previous 28 days) at both week 56 and week 112 of the study (sustained steroid-free clinical remission).

    Time frame: Week 112

Secondary outcomes

  1. Incidence and severity of adverse events in both treatment arms.

    Time frame: week 112

  2. Time to CD worsening in both treatment arms

    Time frame: week 112

  3. Proportion of patients in both treatment arms in steroid-free clinical remission (PRO-2 remission: average AP <=1 and average SF <=3 without any steroid use in the previous 28 days) at week 56 of the study.

    Time frame: Week 56

  4. Proportion of patients in both treatment arms in steroid-free clinical remission (PRO-2 remission: average AP <=1 and average SF <=3 without any steroid use in the previous 28 days) at week 112 of the study.

    Time frame: Week 112

  5. Proportion of patients previously enrolled to UST 90 mg SC Q8w-arm during REScUE who needed dose optimization to ustekinumab 90 mg SC Q4w at the start or during REScUE-OLE (<=week 100), and that reached steroid-free clinical remission at week 112.

    Proportion of patients previously enrolled to the ustekinumab (UST) 90 mg SC Q8w-arm during REScUE who needed dose optimization to ustekinumab 90 mg SC Q4w at the start or during REScUE-OLE (\<=week 100), and that reached steroid-free clinical remission (PRO-2 remission: average AP \<=1 and average SF \<=3 without any steroid use in the previous 28 days) at week 112.

    Time frame: Week 112

  6. Proportion of patients in both treatment arms in clinical remission (PRO-2 remission: average AP <=1 and average SF <=3) at week 56 of the study (sustained clinical remission).

    Time frame: Week 56

  7. Proportion of patients in both treatment arms in clinical remission (PRO-2 remission: average AP <=1 and average SF <=3) at week 56 of the study.

    Time frame: Week 112

  8. Proportion of patients previously enrolled to the ustekinumab 90 mg SC Q8w-arm during REScUE who needed dose optimization to ustekinumab 90 mg SC Q4w at the start or during REScUE-OLE (<=week 100), and that reached clinical remission at week 112.

    Proportion of patients previously enrolled to the ustekinumab 90 mg SC Q8w-arm during REScUE who needed dose optimization to ustekinumab 90 mg SC Q4w at the start or during REScUE-OLE (\<=week 100), and that reached clinical remission (PRO-2 remission: average AP \<=1 and average SF \<=3) at week 112.

    Time frame: Week 112

  9. Proportion of patients in both treatment arms with biomarker remission (CRP <5 mg/L and FC <=250 ug/g) at week 56 of the study.

    Time frame: Week 56

  10. Proportion of patients in both treatment arms with biomarker remission (CRP <5 mg/L and FC <=250 ug/g) at week 112 of the study.

    Time frame: Week 112

  11. Proportion of patients previously enrolled to the ustekinumab 90 mg SC Q8w-arm during REScUE who needed dose optimization to ustekinumab 90 mg SC Q4w at the start or during REScUE-OLE (<=week 100), and that reached biomarker remission at week 112.

    Proportion of patients previously enrolled to the ustekinumab 90 mg SC Q8w-arm during REScUE who needed dose optimization to ustekinumab 90 mg SC Q4w at the start or during REScUE-OLE (\<=week 100), and that reached biomarker remission (CRP \<5 mg/L and FC \<=250 ug/g) at week 112.

    Time frame: Week 112

  12. Proportion of patients in both treatment arms in endoscopic remission (total SES-CD <5) at week 56 of the study.

    Time frame: Week 56

  13. Proportion of patients in both treatment arms in endoscopic remission (total SES-CD <5) at week 112 of the study

    Time frame: Week 112

  14. Proportion of patients previously enrolled to the ustekinumab 90 mg SC Q8w-arm during REScUE who needed dose optimization to ustekinumab 90 mg SC Q4w at the start or during REScUE-OLE (<=week 100), and that reached endoscopic remission (at week 112.

    Proportion of patients previously enrolled to the ustekinumab 90 mg SC Q8w-arm during REScUE who needed dose optimization to ustekinumab 90 mg SC Q4w at the start or during REScUE-OLE (\<=week 100), and that reached endoscopic remission (total SES-CD \<5) at week 112.

    Time frame: Week 112

  15. Proportion of patients in both treatment arms in complete endoscopic remission (total SES-CD <3) at week 56 of the study.

    Time frame: Week 56

  16. Proportion of patients in both treatment arms in complete endoscopic remission (total SES-CD <3) at week 112 of the study.

    Time frame: Week 112

  17. Proportion of patients previously enrolled to UST 90 mg SC Q8w-arm during REScUE who needed dose optimization to ustekinumab 90 mg SC Q4w at the start or during REScUE-OLE (<=week 100), and that reached complete endoscopic remission at week 112.

    Proportion of patients previously enrolled to the ustekinumab (UST) 90 mg SC Q8w-arm during REScUE who needed dose optimization to ustekinumab 90 mg SC Q4w at the start or during REScUE-OLE (\<=week 100), and that reached complete endoscopic remission (total SES-CD \<3) at week 112.

    Time frame: Week 112

Other outcomes

  1. Pharmacokinetic evaluation

    Drug levels in serum

    Time frame: between baseline and week 112

  2. Time until ustekinumab discontinuation (treatment persistence).

    Time frame: between baseline and week 112

  3. Improvements in quality-of-life based on 36-Item Short Form Survey Instrument (SF-36)

    Improvements in quality-of-life based on 36-Item Short Form Survey Instrument (SF-36)

    Time frame: between baseline and week 112

  4. Fatigue as evaluated by the FACIT fatigue scale (functional assessment of chronic illness therapy-fatigue)

    Fatigue as evaluated by the FACIT fatigue scale (functional assessment of chronic illness therapy-fatigue): a 4 point scale, with 0 = not fatigue and 4= very much fatigue

    Time frame: between baseline and week 112

  5. Work productivity as evaluated by the WPAI (work productivity and activity impairment index).

    Work productivity as evaluated by the WPAI (work productivity and activity impairment index).

    Time frame: between baseline and week 112

  6. Pharmaco-economic evaluation

    Pharmaco-economic evaluation of drug cost, hospitalization, work absenteeism, surgery collected and documented during the study

    Time frame: between baseline and week 112

07

Study locations

1 site
  • Ingrid Arijs
    Zaventem, 1930, Belgium
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2021 to primary completion in May 2026, 56 months.

Of 88 phase 3 interventional studies under Crohn Disease, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 69. This study's 56 months is above that.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 13, 2026: primary completion Jun 2026 → May 2026 and completion Jun 2026 → May 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 9, 2022
First posted
Mar 29, 2022
StartActual
Sep 10, 2021
Primary completionActual
May 29, 2026was Jun 2026
CompletionActual
May 29, 2026was Jun 2026
Last update
Oct 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Oct 13, 2026
Primary completion
Jun 2026→May 29, 2026 (actual)
Oct 13, 2026
Study completion
Jun 2026→May 29, 2026 (actual)
Oct 13, 2026
Enrollment
108 (estimated)→41 (actual)
Oct 13, 2026
Show all 1 update
  1. Oct 13, 2026
    Active, not recruiting→Completed
    Primary completion Jun 2026→May 29, 2026 (now actual)
    Study completion Jun 2026→May 29, 2026 (now actual)
    Enrollment 108 (estimated)→41 (actual)
    + 4 other changes: identifiers, verification date, oversight details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05299931
Lead sponsor
Belgian Inflammatory Bowel Disease Research and Development (BIRD) VZW
Responsible party
Sponsor
First posted
Mar 29, 2022
Start date
Sep 10, 2021
Primary completion
May 29, 2026
Completion
May 29, 2026
Last update
Oct 13, 2026

Study contacts

Lieven Pouillon, MD
principal investigator · BIRD VZW

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ustekinumab

Start the discussion